Biological and molecular characterization of fEg-Eco19, a lytic bacteriophage active against an antibiotic-resistant clinical *Escherichia coli* isolate

Shimaa Badawy1,2 · Zakaria A. M. Baka2 · Mohamed I. Abou-Dobara2 · Ahmed K. A. El-Sayed2 · Mikael Skurnik1,3

Received: 17 December 2021 / Accepted: 12 March 2022 / Published online: 10 April 2022 © The Author(s) 2022

**Abstract**

Characterization of bacteriophages facilitates better understanding of their biology, host specificity, genomic diversity, and adaptation to their bacterial hosts. This, in turn, is important for the exploitation of phages for therapeutic purposes, as the use of uncharacterized phages may lead to treatment failure. The present study describes the isolation and characterization of a bacteriophage effective against the important clinical pathogen *Escherichia coli*, which shows increasing accumulation of antibiotic resistance. Phage fEg-Eco19, which is specific for a clinical *E. coli* strain, was isolated from an Egyptian sewage sample. Phage fEg-Eco19 formed clear, sharp-edged, round plaques. Electron microscopy showed that the isolated phage is tailed and therefore belongs to the order *Caudovirales*, and morphologically, it resembles siphoviruses. The diameter of the icosahedral head of fEg-Eco19 is 68 ± 2 nm, and the non-contractile tail length and diameter are 118 ± 0.2 and 13 ± 0.6 nm, respectively. The host range of the phage was found to be narrow, as it infected only two out of 137 clinical *E. coli* strains tested. The phage genome is 45,805 bp in length with a GC content of 50.3% and contains 76 predicted genes. Comparison of predicted and experimental restriction digestion patterns allowed rough mapping of the physical ends of the phage genome, which was confirmed using the PhageTerm tool. Annotation of the predicted genes revealed gene products belonging to several functional groups, including regulatory proteins, DNA packaging and phage structural proteins, host lysis proteins, and proteins involved in DNA/RNA metabolism and replication.

**Introduction**

*Escherichia coli* is a Gram-negative, non-endospore-forming bacterium that is motile by means of peritrichous flagella [1]. It belongs to the family *Enterobacteriaceae* and as a pathogen causes serious urinary and gastrointestinal infections in humans [2, 3]. Furthermore, *E. coli* is used as a contamination indicator for water, food, and agricultural products [4]. It can cause hospital- and community-acquired infections, resulting in diarrhea, meningitis, urinary tract infections (UTIs), bacteremia, pneumonia, surgical-site infections, and sepsis [3]. It can also cause food-borne infections, such as those caused by enterohemorrhagic *E. coli* (EHEC) or Shiga-toxin-producing *E. coli* (STEC). STEC can be acquired by ingestion of contaminated food or water, or through contact with animals or their environment [5]. The worldwide increase in the rate of resistance to carbapenem and colistin among members of the family *Enterobacteriaceae* [6], especially in developing countries [7], is a serious threat to their therapeutic use. In addition, antibiotic resistance in foodborne *E. coli* remains a public health
concern and is responsible for severe infections in humans [8]. The changing patterns of antimicrobial resistance and shortage of novel classes of antibiotics [9] have contributed to a demand for new antibacterial agents. This has occurred despite the introduction of carbapenem (imipenem and meropenem) and colistin (polymyxin B), which are the last-resort antibiotics for treatment of Gram-negative bacterial infections. Resistant strains against both antibiotics have been widely reported in clinical settings [10, 11]. Moreover, pan-resistant strains, resistant to all available antibiotics, have been encountered [12]. Due to this threat, phage therapy is being developed and used as an alternative treatment to manage infections caused by multidrug-resistant (MDR) pathogens [13–15]. Compared to antibiotics, phages have several advantages that enable them to be good therapeutic agents. Phages are generally considered safe, as they do not infect animal or plant cells, they are highly specific for a particular host, they replicate only at the site of infection where their target bacteria are present, and they very effectively lyse only the target pathogen and not the bacteria of normal microbiome. The mechanism by which they kill bacteria is different from that of antibiotics, so they are also effective against MDR bacteria. Furthermore, phage propagation is inexpensive, phages are ubiquitous in nature, and side effects are uncommon in phage therapy [16–18].

Phage therapy, the use of lytic bacteriophages to combat bacterial infectious diseases, is regarded as a promising alternative to the use of antimicrobial agents [19, 20]. Bacteriophages and their derived enzymes can be seen as an appealing alternative for treatment of drug-resistant infections [21]. Phage therapy is a realistic complement to antibiotics, especially now that recent modifications to ubiquitous phages have made them more controllable. There is still a need for a better understanding of phage therapy, however, before it can be adopted widely [22, 23]. In this work, we characterized an Escherichia phage isolated from an Egyptian sewage sample.

Materials and methods

Bacterial strains

The bacterial strains used for phage isolation and host range determination are listed in Supplementary Table S1. The bacteria were cultured in lysogeny broth (LB) or on LB agar (LA) plates as described previously [24].

Phage isolation and purification

E. coli-specific bacteriophages were enriched as described previously [25], with some alterations. Sewage water samples used as sources of phages were collected during winter 2018 from four El-Rezka and El-Korama drainages, Dakahlia Governorate, Egypt. Five drainage samples of each location were collected in sterile 50-ml polypropylene tubes. The samples were centrifuged at 5,000 rpm for 15 min at 4°C, and the supernatants were filtered through 0.45-µm filters (Minisart® Sartorius, Göttingen, Germany) to remove any remaining bacteria, and then combined together. Thirteen clinical E. coli strains (Supplementary Table S1, indicated in bold) were grown separately at 37°C for 16 h. Two parallel pools, representing six and seven strains, respectively, were prepared by combining 100-µl aliquots of the cultures. To these pools, one ml of the filtered Egyptian sewage mixture was added, followed by 9 ml of LB. These cultures were incubated for 16 h on a rocking platform at 37°C to enrich any E. coli-specific phages present in the sewage samples. To kill the bacteria, chloroform (0.2 ml for every 3 ml of culture) was added to the tubes, followed by mixing on the rocking platform for 20 min at 22°C. The lysates were then centrifuged at 5,000 rpm for 10 min at 4°C, and the supernatants were passed through 0.45-µm filters (Minisart® Sartorius). The resulting enriched lysates were stored at 4°C and used to isolate E. coli specific-phages. Phage isolation, titration, plaque purification, and preparation of phage stocks were carried out as described previously [24].

Transmission electron microscopy

Phage particles were concentrated by centrifugation for 90 min at full speed (16,000 × g) in an Eppendorf centrifuge (5415R, rotor model 3328, Enfield, NJ, USA), and the pelleted phages were resuspended in 200 µL of 0.1 M ammonium acetate, pH 7.0. Three 3-µl aliquots of the high-titer phage preparations (10¹⁰–10¹³ plaque-forming units/mL) were pipetted on carbon-coated copper grids. After allowing the phages to adsorb for one minute, the grids were stained with 2% uranyl acetate (pH 4.2) for 30 s. The grids were then examined for phages using a transmission electron microscope (JEOL JEM-1400, Tokyo, Japan) at 80 kV beam voltage, equipped with a Gatan Orius SC 1000B camera (Gatan Inc., Pleasanton, CA, USA). The heads and tails of 5 to 10 individual phage particles were measured and used to calculate the averages and standard errors for the dimensions.

Phage host range determination

The host range of fEg-Eco19 was tested on 152 strains, including 137 E. coli strains, 10 Staphylococcus aureus strains, two Pseudomonas aeruginosa strains, two Acinetobacter baumannii strains, and one Klebsiella pneumoniae strain. The phage sensitivity was assayed using the Bioscreen C system (Growth Curves, Helsinki, Finland), in which bacterial growth is measured continuously by vertical photometry (optical density) at 600 nm using a
Phage and bacterial DNA extraction

Phage DNA was extracted using the phenol chloroform method [27], with some previously described modifications [24]. The bacterial genomic DNA was isolated and purified using a JetFlex Genomic DNA Purification Kit (Thermo Fisher Scientific, Waltham, MA, USA), following the manufacturer’s instructions. The quality and quantity of DNA was determined using a NanoDrop spectrophotometer (ND-1000, Wilmington, DE, USA), a Qubit 2.0 fluorometer (Invitrogen, CA, USA) with a Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific), and agarose gel electrophoresis [28].

Phage genome sequencing, assembly, and bioinformatics

Phage genome sequencing, assembly, and bioinformatics were performed as described previously [24]. A phylogenetic tree based on the phage proteome was generated using VITPtree [29]. The termini of the phage genome were identified using the Phage Term program [30].

Restriction enzyme digestion

The purified phage DNA was digested with the restriction endonucleases EcoRI, NsiI, Smal, Sall, NruI (Thermo Fisher Scientific), Clal, AlIII, and BbvCI (New England Biolabs), which were predicted to produce the best-resolved restriction fragment patterns. The restriction enzyme digestions, using ca. 300 ng of phage DNA, were carried out according to manufacturers’ instructions in a final volume of 10 µL. The restriction fragments were separated by electrophoresis in a 1% (w/v) agarose gel containing 0.005% (w/v) of Midori green. The restriction fragment bands were visualized using a Bio-Rad GelDoc XR+ imaging system.
Phage host range

The host range of phage fEg-Eco19 was investigated using 137 *E. coli* strains and 15 strains representing other species (Supplementary Table S1), using the Bioscreen C method, in which the growth is measured continuously by vertical photometry (optical density) at 600 nm. Bacterial growth curves (Fig. 3) revealed that the phage infected only *E. coli* strains #5521 and #5765. Both of these are clinical strains. While strain #5521 is a blood culture isolate that is sensitive to most antibiotics, #5765 is an ESBL strain isolated from a urine sample. The growth curves of the phage-infected cultures showed that spontaneous phage-resistant mutants of #5765 started to grow after the 6 h time point. No such growth was observed for #5521, suggesting that these strains do not share a common phage receptor, and the plaques on #5765 were similar to those on #5521. Further studies are needed to identify the receptors.

Characterization of the phage genome

Assembly of the Illumina sequence reads of phage fEgEco-19 revealed that it has a genome of about 45 kb. Of the total sequence reads, 98.8 % mapped to the 45-kb contig, indicating that it represents the complete phage genome. The fEg-Eco19 genome is 45,805 bp in size with a GC-content of 50.2%. PhageTerm analysis allowed the identification of the physical genome termini and revealed that fEgEco-19 uses the phage P1-type headful packaging mechanism, starting from a pac site (Supplementary Fig. S1). Phages that use a

| Bacteriophage | Morphology | Head | Tail |
|---------------|------------|------|------|
|               |            | Shape | Capsid size (nm) | Type | length (nm) | Width (nm) |
| fEg-Eco19     | Siphovirus | Icosahedral | 68 ± 2 | Long non-contractile | 118 ± 0.2 | 13 ± 0.6 |

![Fig. 2](image-url) Transmission electron micrograph of fEg-Eco19 negatively stained with 2% uranyl acetate

![Fig. 3](image-url) Bacterial growth patterns for host range determination using the Bioscreen C system, in which growth is measured continuously by vertical photometry (optical density) at 600 nm. The results revealed that this phage is highly specific, as it infected only *E. coli* strains #5521 and #5765.
A lytic Escherichia coli bacteriophage

Headful packaging mechanism typically generate a concatemer containing several copies of their genome. The phage terminase initiates packaging of the genome concatemer at the specific pac site, and packaging is terminated at variable positions when the phage head becomes full. This leads to capsids containing circularly permuted genomes with somewhat random termini used to circularize the phage genome through recombination after injection into the host cell [30]. In PhageTerm analysis, a slight increase in read start coverage is expected in the region after the pac site peak where the second cut is made, since starts in this region will be present in many phage particles. Since packaging is directional and no precise cut is made upon termination of packaging, a peak is expected only in a single orientation, which also informs us about the direction of packaging [30]. Restriction enzyme digestions were used to confirm the PhageTerm-predicted physical ends of the phage (Fig. 4).

The experimental restriction enzyme digestion patterns of phage fEg-Eco19 DNA (Fig. 4) were in perfect agreement with in silico-predicted restriction digestion fragment sizes, confirming that the genome sequence was correctly organized based on the identification of the physical ends by PhageTerm analysis:

**EcoRI** (40224, 3565, 1155 left end, 762 right end, 99)

**NsiI** (34390, 5641 right end, 2354, 1848 left end, 1572)

**SmaI** (11409, 11224, 8310, 8962 right end, 5239, 3099 left end, 698)

**SalI** (14431, 11244 left end, 5290, 5077 right end, 3077, 2236, 2192, 1745, 513)

**NruI** (11937, 10679, 8264, 6109, 5971 right end, 2748 left end, 97)

**ClaI** (13004, 10790, 7310, 6919, 2859, 2589, 1032, 908 right end, 358 left end)

**AflII** (8086, 7462, 5659, 5230, 5218 left end, 4285, 2979, 2718, 1620, 1352, 1196 right end)

**BbvCI** (23652 left end, 22153 right end)

### Annotated genome map and phylogenetic analysis

Annotation of the sequences showed that the fEg-Eco19 genome contains 76 predicted genes and has a GC content of 50.2%. The overall organization of the genome of fEg-Eco19 is presented in Figure 5. A BLASTn search of the databases identified a number of *Escherichia* phages that are related to fEg-Eco19, with fEgEco02 (accession no. MT711523) being the closest, with 93.07% identity and 80% query coverage. On the other hand, phylogenetic analysis carried out using ViPtree showed fEg-Eco19 to be most closely related to Raoultella phage RP180 (accession no. NC_048181) and a number of *Escherichia* phages, all with siphovirus morphology (Fig. 6), although the BLASTn search showed fEg-Eco19 to have 90.28% identity to RP180, with 73% query coverage.

### Predicted functions of the phage gene products

The predicted functions of the phage gene products (Gps), based on database searches (Supplementary Table S2), revealed the presence of the following functional groups:

**Regulatory proteins:** A transcriptional regulator (Gp16), a transcriptional repressor (DicA, Gp67), a regulatory protein (cox, Gp71c), and superinfection immunity protein (Gp43c) likely involved in gene regulation [31] were identified.

**DNA packaging and phage structural proteins:** Gp18 is the homolog of the DNA-packaging protein gp3 complex of *Bacillus* phage ϕ29, which is the packaging substrate to which DNA must attach for efficient DNA packaging [32]. DNA is packaged into the cavity of a preformed protein shell, called the prohead, through the connector located at

---

Fig. 4 Agarose gel electrophoresis analysis of restriction-enzyme-digested fEg-Eco19 DNA. Phage genomic DNA was digested with EcoRI (lane 2), NsiI (lane 3), SmaI (lane 4), SalI (lane 5), NruI (lane 6), ClaI (lane 7), AflII (lane 8), and BbvCI (lane 9). Lane 1, undigested DNA. Lane M, 1-kb DNA ladder.
Fig. 5 The annotated genome map of fEg-Eco19. The predicted genes are shown as colored arrows labelled with predicted functions (genes encoding structural proteins, brown; DNA/RNA-manipulating proteins, blue; hypothetical proteins, grey; other enzymes, red; lysis functions, green; regulatory proteins, yellow. The map was drawn with Geneious 10.2.6 (www.geneious.com). HP, hypothetical protein; pr, protein.

Fig. 6 Position of fEg-Eco19 in a phage proteomic tree generated using VIPTree [42] (accessed on Nov. 15, 2021). (A) A circular proteomic tree of prokaryotic dsDNA viruses colored according to virus family and host taxonomic group (B) Part of the rectangular presentation of the proteomic tree showing the phages most closely related to fEg-Eco19. The location of fEg-Eco19 in both is indicated by a red asterisk. (C) Alignment of the fEg-Eco19 genome sequence with that of Raoultella phage RP180.
the portal vertex, with the aid of a non-capsid protein called "terminase" or "packaging enzyme" [33, 34]. Packaging of DNA into the phage head is carried out by the putative terminase (Gp19), which recognizes the cos site, where it introduces nicks to generate the cohesive ends of the genome and separates the cohesive ends in a reaction requiring ATP hydrolysis [35]. The terminase and the phage portal proteins (Gp20) are believed to be the initiators of head assembly. The phage structural proteins are encoded by genes in the left half of the genome (Fig. 5) and include Gp21, Gp28, and Gp29, which are annotated as head protein, major head protein, and major capsid protein, respectively, and initiate formation of the procapsid [36]. Gp30 is the head fiber protein, Gp31 is the decoration protein, Gp32 is the head-tail joining protein, Gp33 is the head-to-tail connector complex protein, and Gp35 is the head-to-tail connector complex protein. Gp46 is a putative tape measure protein, Gp22 and Gp37 are annotated as tail proteins, Gp36 is a putative tail protein, and Gp38 is a putative tail tube protein. Gp48 is annotated as a distal tail protein, Gp51 as a putative tail protein, and Gp52 as a tail spike protein (Supplementary Table S2).

**Host lysis proteins:** HHpred analysis detected some similarity between Gp1 and the cell division protein ZAPB, which is an abundant cell division factor required for proper Z-ring formation. It is recruited early to the site of division by direct interaction with FtsZ, stimulating Z-ring assembly and thereby promoting cell division earlier in the cell cycle. Its recruitment to the Z-ring requires functional FtsA or ZipA [37]. Gp7 and GP8 are predicted to be holin-like class II and holin-like class I proteins, respectively. Gp9 is predicted to be a putative endolysin functioning as a phage-encoded peptidoglycan hydrolase that breaks down the bacterial peptidoglycan at the end of the reproduction cycle to release the viral progeny [38]. Endolysins have significant advantages over classical antibiotics, including narrow host specificity, high sensitivity, and low probability of development of resistance [39]. Gp25 is predicted to be a spanin, which is a lysis protein that is required for outer membrane disruption. Most phases produce a two-component spanin complex. Gp27 is predicted to be the o-spanin, an outer membrane lipoprotein, and Gp25 is predicted to be the inner membrane protein (i-spanin), which contains a predominantly coiled-coil periplasmic domain. Spanins play an essential role in lysis downstream of the holin-endolysin steps [40].

**DNA/RNA-manipulating proteins and replication gene products:** Gp13 was predicted to be the DNA-directed RNA polymerase (RNAP), which catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Classification of phage transcriptional regulatory mechanisms is primarily based on the presence or absence of a phage RNAP. Gp14 was predicted to be the DNA-directed RNA polymerase subunit alpha, which plays an important role in subunit assembly, since its dimerization is the first step in the sequential assembly of subunits to form the holoenzyme [41]. Gp23 was predicted to be the DNA polymerase III sliding clamp, also known as a β-clamp, a protein complex that promotes DNA replication. As a major component of the DNA polymerase III holoenzyme, the clamp protein binds DNA polymerase and prevents this enzyme from dissociating from the template DNA strand. The clamp-polymerase protein–protein interactions are stronger and more specific than the direct interactions between the polymerase and the template DNA strand. The presence of the DNA clamp can increase the rate of DNA synthesis up to 1,000-fold compared with a non-processive polymerase [42]. The HNH endonucleases (Gp26 and Gp54) can nick the double-stranded DNA and may play a variety of roles in replication, recombination, repair pathways, and pathogenicity [31, 43]. In addition, catalytic HNH motifs were identified in Gp39 and Gp56c. Gp58c is annotated to be a restriction endonuclease. Gp61c shows similarity to the T4 DNA polymerase Klenow fragment. Gp62c is annotated to be involved in DNA replication. Gp63c contains a DUF2815 domain and is predicted to be a PD-(D/E)XXK nuclease superfamily protein. These proteins are involved in numerous nucleic acid cleavage events that are important for various cellular processes [44]. The DNA helicases Gp55c and Gp68c unwind the DNA to create a template for DNA replication [45].

**Other enzymes:** Gp6 is predicted to be an ATP-dependent protease, a universal barrel-like, ATP-fueled machine that prevents the accumulation of aggregated proteins and regulates the proteome according to the demands of the cell. These proteases are distinguished by two separate operating units, the ATPase and peptidase domains. ATP-dependent unfolding and translocation of a substrate into the proteolytic chamber is followed by ATP-independent degradation [46]. Gp12 is predicted to be a proline/betaine transporter, a proton symporter that senses osmotic shifts and responds by importing osmolytes such as proline, glycine, betaine, stachydrine, picolic acid, ectoine, and taurine. It is both an osmosensor and an osmoregulator that is available to participate early in the bacterial osmoregulatory response [47]. Gp42 is predicted to be a phosphoesterase that, during phage infection, might negatively regulate the growth of the phage, and perhaps of the host as well [48]. Gp50 is annotated to be a putative dipeptidyl peptidase VI. Gp74 is homologous to glycoside hydrolases with lysozyme activity (EC 3.2.1.17). This family includes the lambda phage lysozyme and E. coli endolysin [49]. Lysozyme helps mature phage particles to be released from the cell by breaking down the peptidoglycan of the cell wall. It hydrolyses 1,4-beta linkages between N-acetyl-D-glucosamine and N-acetylmuramic acid in peptidoglycan heteropolymers of prokaryotic cell walls. E. coli endolysin also functions in bacterial cell lysis and acts as a transglycosylase.
Conclusion

In this work, we characterized the *Escherichia coli*-infecting phage fEg-Eco19, which was originally isolated from a sewage sample in Egypt. The phage genome is 45,805 bp in length, containing 76 predicted genes. Based on electron microscopy and phylogenetic analysis, it belongs to the order *Caudovirales* and morphologically resembles siphoviruses. Phage fEg-Eco19 was able to infect only two of the 137 clinical *E. coli* strains tested, and none of the *S. aureus*, *P. aeruginosa*, *A. baumannii*, and *K. pneumoniae* strains tested, indicating that it has a narrow host range. The genome of phage fEg-Eco19 showed a high level of sequence similarity (87.99% identity) to the *Escherichia* phage vB_EcoS_HSE2 (accession no. MG252615.1). Restriction digestion patterns allowed rough mapping of the physical ends of the phage genome, which were identified exactly using the PhageTerm tool. Annotation of the predicted genes revealed gene products of several functional groups, including regulatory proteins, DNA packaging and phage structural proteins, host lysis proteins, and proteins involved in DNA/RNA metabolism and replication.

Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s00705-022-05426-6.

Acknowledgements  This research was funded by Damietta University grants to S.B. and by Academy of Finland (project 288701) and Jane and Aatos Erkko Foundation grants to M.S.

Funding  Open Access funding provided by University of Helsinki including Helsinki University Central Hospital.

Declarations

Conflict of interest  The authors declare no conflict of interest.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Welch RA (2006) The genus *Escherichia*. In: Dworkin M, Falkow S, Rosenberg E, Schleifer K-H, Stackebrandt E (eds) Prokaryotes, vol 6, 3rd edn. Springer Science Business Media, New York, pp 60–71

2. Morens DM, Folkers GK, Fauci AS (2004) The challenge of emerging and re-emerging infectious diseases. Nature 430:242–249

3. Schlossberg D (2015) Clinical infectious disease. Cambridge University Press, Cambridge

4. Reid G, Howard J, Gan B (2001) Can bacterial interference prevent infection? Trends Microbiol 9(9):424–428

5. Balasubramanian S, Osbourne M, BrinJones H, Tai A, Leong J (2019) Prophage induction, but not production of phage particles, is required for lethal disease in a microbiome-replete murine model of enterohemorrhagic *E. coli* infection. PLoS Pathog 15(1):e1007494

6. World Health Organization [WHO] (2014) Antimicrobial resistance: global report on surveillance 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 20 Oct 2016

7. Ventola CL (2015) The antibiotic resistance crisis: part 1: causes and threats. Pharm Therapeut 40:277–283

8. Barilli E, Vismarra A, Villa Z, Bonilauri P, Bacci C (2019) ESbeta. *E. coli* isolated in pig’s chain: genetic analysis associated to the phenotype and biofilm synthesis evaluation. Int J Food Microbiol 289:162–167

9. Livermore DH (2004) The need for new antibiotics. Clin Microbiol Infect 10:1–9

10. Nordmann P, Poirel L (2002) Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 8:321–331

11. Cai Y, Chai D, Wang R, Liang B, Bai N (2012) Colistin resistance of *Acinetobacter baumannii*: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67:1607–1615

12. Wand ME, Bock LJ, Bonney LC, Sutton JM (2015) Retention of virulence following adaptation to colistin in *Acinetobacter baumannii* reflects the mechanism of resistance. J Antimicrob Chemother 70:2209–2216

13. Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ (2008) Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol 104:1–13

14. Burrowes B, Harper D, Anderson J, McConville M, Enright M (2011) Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti-Infect Ther 9:775–785

15. Hyman P (2019) Phages for phage therapy: isolation, characterization, and host range breadth. Pharmaceuticals 12:35

16. Garcia P, Monjardin C, Martin R, Madera C, Soberon N, Garcia E, Meana A, Suarez J (2008) Isolation of new Stenotrophomonas bacteriophages and genomic characterization of temperate phage S1. Appl Environ Microbiol 74:7552–7560

17. Loc-Carrillo C, Abedon S (2011) Pros and cons of phage therapy. Bacteriophage 1:111–114

18. Chang Y, Jaewoo B, Ju-Hoon L, Sangryeol R (2019) Mutation of a *Staphylococcus aureus* temperate bacteriophage to a virulent one and evaluation of its application. Food Microbiol 82:523–532

19. Vieira A, Silva Y, Cunha Â, Gomes N, Ackermann H, Almeida A (2012) Phage therapy to control multidrug-resistant *Pseudomonas aeruginosa* skin infections: in vitro and ex vivo experiments. Eur J Clin Microbiol Infect Dis 31:3241–3249

20. Wittebole X, De Rook C, Opal S (2014) A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathologies. Virulence 5(1):226–235

21. Drulis-Kawa Z, Majkowska-Skropek G, Maciejewska B (2015) Bacteriophages and phage-derived proteins application approaches. Curr Med Chem 22:1757–1773

22. Moradpour Z, Ghasemian A (2011) Modified phages: novel antimicrobial agents to combat infectious diseases. Biotechnol Adv 29(6):732–738
23. Kortright KE, Chan BK, Koff JL, Turner PE (2019) Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 25(2):219–232

24. Badawy S, Pajunen MI, Haiko J, Baka ZAM, Abou-Dobara M, El-Sayed AKA, Skurnik M (2020) Identification and functional analysis of temperate siphoviridae bacteriophages of Acinetobacter baumannii. Viruses 12(6):604

25. Baker PM, Farmer JJ (1982) New bacteriophage-typing system for Yersinia enterocolitica, Yersinia kristensenii, Yersinia frederiksenii, and Yersinia intermedia—correlation with serotyping, biotyping, and antibiotic susceptibility. J Clin Microbiol 15:491–502

26. Cooper CJ, Denyer SP, Maillard JY (2011) Rapid and quantitative automated measurement of bacteriophage activity against cystic fibrosis isolates of Pseudomonas aeruginosa. J Appl Microbiol 110(3):631–640

27. Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual, 3rd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor

28. Karumidze N, Kusradze I, Rigvava S, Goderdzishvili M, Rajakumar K, Alavidze Z (2013) Isolation and characterisation of lytic bacteriophages of Klebsiella pneumoniae and Klebsiella oxytoca. Curr Microbiol 66:251–258

29. Nishimura Y, Yoshida T, Kuronishi M, Uehara H, Ogata H, Goto S (2017) ViPTree: the viral proteomic tree server. Bioinformatics 33:2379–2380

30. Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M (2017) PhageFerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data. Sci Rep 7(1):8292. https://doi.org/10.1038/s41598-017-07910-5

31. Mitsunobu H, Zhu B, Lee S, Tabor S, Richardson C (2014) Flap endonuclease of bacteriophage T7: possible roles in RNA primer removal, recombination and host DNA breakdown. Bacteriophage 4:e28507

32. Bjornsti MA, Reilly BE, Anderson DL (1982) Morphogenesis of bacteriophage f-29 of Bacillus subtilis: DNA-gp3 intermediate in vivo and in vitro assembly. J Virol 41:508–517

33. Earnshaw WC, Casjens SR (1980) DNA packaging by the double-stranded DNA bacteriophages. Cell 21:319–331

34. Black LW (1989) DNA packaging in dsDNA bacteriophage. Annu Rev Microbiol 43:267–292

35. Duffy C, Feiss M (2002) The large subunit of bacteriophage λ’s terminase plays a role in DNA translocation and packaging termination. J Mol Biol 316:547–561

36. Rajagopala S, Casjens S, Uetz P (2011) The protein interaction map of bacteriophage lambda. BMC Microbiol 11:213

37. Ebersbach G, Galli E, Müller-Jensen J, Löwe J, Gerdes K (2008) Novel coiled-coil cell division factor ZapB stimulates Z ring assembly and cell division. Mol Microbiol 68(3):720–735

38. Schmelcher M, Donovan DM, Loessner MJ (2012) Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7:1147–1171

39. Borysowski J, Weber-Dabrowska B, Görski A (2006) Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med 231:366–377

40. Cahill J, Young R (2019) Phage lysis: multiple genes for multiple barriers. Adv Virus Res 103:33–70

41. Igarashi K, Ishihama A (1991) Bipartite functional map of the E. coli RNA polymerase alpha subunit: involvement of the C-terminal region in transcription activation by cAMP-CRP. Cell 65(6):1015–1022

42. Mizrahi V, Henrie R, Marlier J, Johnson K, Benkovic S (1985) Rate-limiting steps in the DNA polymerase I reaction pathway. Biochemistry 24(15):4010–4018

43. Xu SY (2015) Sequence-specific DNA nicking endonucleases. Biomol Concepts 6:253–267

44. Knizewski L, Kinch L, Grishin N, Rychlewski L, Ginalski K (2007) Realm of PD-(D/E)XK nuclease superfamily revisited: detection of novel families with modified transitive meta profile searches. BMC Struct Biol 7:40

45. Lionnet T, Spiering M, Benkovic S, Bensimon D, Croquette V (2007) Real-time observation of bacteriophage T4 gp41 helicase reveals an unwinding mechanism. Proc Natl Acad Sci USA 104:19790–19795

46. Bittner LM, Arends J, Narberhaus F (2016) ATP-dependent proteases in bacteria. Biopolymers 105:505–517

47. Culham DE, Lasby BL, Marangoni AG, Milner JL, Steer BA, van Nues RW, Wood JM (1993) Isolation and sequencing of Escherichia coli gene proP reveals unusual structural features of the osmoregulatory proline/betaine transporter. ProP J Mol Biol 5229(1):68–76

48. Dutta S, Bhawsinghka N, Das Gupta K (2014) Gp66, a calcineurin family phosphatase encoded by mycobacteriophage D29, is a 2',3' cyclic nucleotide phosphodiesterase that negatively regulates phage growth. FEMS Microbiol Lett 361(1):84–93

49. Weaver LH, Matthews BW (1987) Structure of bacteriophage T4 lysozyme refined at 1.7 Å resolution. J Mol Biol 193(1):189–199

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.